Artículo
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Autor/es | González-Serna Martín, Manuel Alejandro
Macías Sánchez, Juan Corma Gómez, Anais Tellez, Francisco Cucurull, Josep Real Navarrete, Luis Miguel Granados, Rafael Rivero Juárez, Antonio Hernández Quero, José Merino, Dolores Palacios, Rosario Ríos-Villegas, María José Collado, Antonio Pineda Vergara, Juan Antonio |
Departamento | Universidad de Sevilla. Departamento de Fisiología Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2022-09 |
Fecha de depósito | 2024-04-05 |
Publicado en |
|
Premios | Premio Trimestral Publicación Científica Destacada de la US. Facultad de Farmacia |
Resumen | Objectives
Real world data on glecaprevir/pibrentasvir (G/P) among active drug users are scarce. We evaluated the sustained virological response (SVR) rates of G/P among individuals with and without active drug use in ... Objectives Real world data on glecaprevir/pibrentasvir (G/P) among active drug users are scarce. We evaluated the sustained virological response (SVR) rates of G/P among individuals with and without active drug use in routine clinical practice. Methods Two ongoing prospective multicenter cohorts of individuals starting G/P were analyzed. Overall SVR intention-to-treat (ITT), discontinuations due to adverse effects and dropouts were evaluated. Results in patients with active, past and without active drug use were compared. Results Overall, 644 individuals started G/P and have reached the date of SVR evaluation. Of them, 613 (95.2%) individuals achieved SVR. There were two (0.3%) relapses, one (0.2%) discontinuation due to side effects and 35 (5.4%) dropouts. SVR rates for patients with active drug use, past drug use and those who never used drugs were 85.4%(n/N = 70/82), 96.1%(n/N = 320/333) and 97.4%(n/N = 223/229) respectively (p < 0.001). After adjustment by sex, age, HCV genotype and opioid agonist therapy, active drug use was the only factor independently associated with SVR (ITT) [adjusted OR (95%confidence interval): 0.29(0.09–0.99),p = 0.048]. Conclusions Active drug use was independently associated with lower SVR rates to G/P, mainly due to voluntary dropout. G/P could be particularly beneficial in this scenario but specific strategies designed to increase the retention in care are needed. |
Agencias financiadoras | Instituto de Salud Carlos III European Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER) Ministerio de Ciencia, Innovación y Universidades (MICINN). España Servicio Andaluz de Salud |
Identificador del proyecto | PI018/00606
CP18/00146 CP18/00111 CM19/00251 B-0061-2021 A1-0060-2021 |
Cita | González-Serna Martín, M.A., Macías Sánchez, J., Corma Gómez, A., Tellez, F., Cucurull, J., Real Navarrete, L.M.,...,Pineda Vergara, J.A. (2022). High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use. Journal of Infection, 85 (3), 322-326. https://doi.org/10.1016/j.jinf.2022.06.005. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
10.1016j.jinf.2022.06.005.pdf | 300.3Kb | [PDF] | Ver/ | Versión aceptada |